| Market Cap | 5.96M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.03M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -40.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -50.00% |
| Dividend | N/A | Price/Book | 9.26 | EPS next 5Y | - | 52W High Chg | -88.00% |
| Recommedations | - | Quick Ratio | 6.16 | Shares Outstanding | 2.25M | 52W Low Chg | 1.00% |
| Insider Own | 20.48% | ROA | -87.33% | Shares Float | 1.98M | Beta | -0.16 |
| Inst Own | 7.93% | ROE | -163.33% | Shares Shorted/Prior | 34.59K/9.57K | Price | 3.23 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 126,453 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 61,155 | Change | -6.10% |
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bernards Rene | Director Director | Oct 02 | Buy | 2.4 | 10,000 | 24,000 | 25,000 | 10/05/23 |
| van der Baan Bastiaan Jeroen | President and CEO President and CEO | Oct 03 | Buy | 2.80 | 10,000 | 28,000 | 11,000 | 10/05/23 |
| Bernards Rene | Director Director | Dec 15 | Buy | 0.51 | 15,000 | 7,650 | 150,000 | 12/16/22 |
| FORMAN ERIC | Vice President and C.. Vice President and COO | Nov 17 | Buy | 0.56 | 21,059 | 11,793 | 98,142 | 11/21/22 |
| Bernards Rene | Director Director | Nov 14 | Buy | 0.53 | 52,500 | 27,825 | 125,000 | 11/15/22 |